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Abstract Survival of retinal ganglion cells (RGC) is
compromised in several vision-threatening disorders such
as ischemic and hypertensive retinopathies and glaucoma.
Pigment epithelium-derived factor (PEDF) is a naturally
occurring pleiotropic secreted factor in the retina. PEDF
produced by retinal glial (Mu ¨ller) cells is suspected to be
an essential component of neuron-glial interactions espe-
cially for RGC, as it can protect this neuronal type from
ischemia-induced cell death. Here we show that PEDF
treatment can directly affect RGC survival in vitro. Using
Mu ¨ller cell-RGC-co-cultures we observed that activity of
Mu ¨ller-cell derived soluble mediators can attenuate
hypoxia-induced damage and RGC loss. Finally, neutral-
izing the activity of PEDF in glia-conditioned media par-
tially abolished the neuroprotective effect of glia, leading
to an increased neuronal death in hypoxic condition.
Altogether our results suggest that PEDF is crucially
involved in the neuroprotective process of reactive Mu ¨ller
cells towards RGC.
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Introduction
Pigment epithelium-derived factor (PEDF) is a 50 kDa
glycoprotein that belongs to the non-inhibitory serpin
family [1] and is a key anti-angiogenic molecule [2, 3]. In
retina it has been shown that PEDF is not only produced by
the pigmented epithelium [4] but also by Mu ¨ller glial cells
[5, 6] and that it can counterbalance elevated levels of pro-
angiogenic vascular endothelial growth factor (VEGF)
[7, 8] In the eye, PEDF is therefore critically involved in
the pro-/anti angiogenic balance provided by reactive glia
in response to a hypoxic insult [9, 10]. In addition, PEDF
has been recognized as an important endogenous anti-
oxidative and anti-inﬂammatory factor [11–13]. Vitreous
levels of PEDF were signiﬁcantly decreased in prolifera-
tive diabetic retinopathy, suggesting that reduction of
PEDF in the retina may contribute to the pathogenesis of
this disease by worsening the retinal inﬂammation [12, 14].
PEDF not only suppresses pathological neovascularization
and inﬂammation, but in addition to its anti-angiogenic and
anti-inﬂammatory properties PEDF exerts neuroprotective
and neurotrophic effects [15, 16] that are mediated by
activation of NF-jB and ERK-1/-2 pathways [17]. In
retina PEDF protects neurons from light-induced damage,
oxidative stress [18], as well as from apoptosis in mouse
models of inherited retinal degeneration [19, 20]. PEDF
has also been shown to protect rat retinal ganglion cells
(RGC) from glutamate- to trophic factor withdrawal-med-
iated cytotoxicity [17]. In addition, PEDF protects RGCs
from ischemia-induced neuronal cell death, reducing RGC
loss [21]. Moreover, Zhou et al. [22] showed that PEDF
reduces RGC loss and vision decline in DBA/2 J mice [22],
a mouse model for inherited glaucoma [23, 24], the second
leading causes of blindness in human [25]. PEDF-induced
neuroprotection of RGC may therefore represent a
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states targeting speciﬁcally this neuronal type [26].
However, even if there are evidence for PEDF receptors
at RGC surface [27, 28] no data exists concerning the
direct effect of PEDF on this neuronal type. Most of the
literature focuses either on global neuroprotection in vivo
[22, 29] or consists in PEDF treatment of retinal mixed
cultures in which RGC neurons represent only a small
fraction of the total cells [17, 18]. It is therefore unclear
whether RGC can directly respond to the PEDF stimulus or
whether this effect is mediated via another cell type. In the
latter case, survival of RGC would be an indirect conse-
quence of the PEDF release. This prompted us to study
these unknown aspects by treating pure RGC cultures with
PEDF and analyzing its effects on neuronal survival in
normal and hypoxic conditions.
The speciﬁc role of glial PEDF in the retina is also
unclear as most of the earlier studies were based on in-
travitreal injections of PEDF protein or adenovirus-medi-
ated delivery of the PEDF gene [21, 30, 31] barely
affecting RGC which are separated from the retinal pig-
ment epithelium (RPE) by the whole retinal thickness.
Indeed the 50 kDa PEDF molecule secreted by RPE is
theoretically able to cross the outer limiting membrane and
all retinal layers, according to the permability properties of
the retinal tissue [32], but injection of ﬂuorescent-serpin
clearly showed its accumulation in the photoreceptor layer
whereas no signal was found in the RGC layer [33].
Therefore, to achieve PEDF-mediated neuroprotection of
this particular neuronal type, another source is needed
which could consist in Mu ¨ller glial cells via their endfeet
closely surrounding each RGC. Moreover, it has largely
been documented that Mu ¨ller glial cells are able to rapidly
increase their level of PEDF release in response to ocular
injury or hypoxia [8, 10, 34]. Therefore, PEDF might act
more effectively on RGC when produced by their glial
neighbour cells, and intraretinal PEDF levels governed by
Mu ¨ller cells may represent the very ﬁrst line of defence
against RGC aggressions. With this hypothesis in mind we
have assessed the levels of PEDF expression in Mu ¨ller
cells as compared to other retinal cells. Using the model of
pure RGC culture that we have developed recently from
mice [35, 36] we further examined whether release of glia-
derived PEDF is sufﬁcient to achieve neuroprotective
effects.
Materials and Methods
Materials
Supplements of culture media were from Sigma-Aldrich
(Taufkirchen, Germany) unless otherwise indicated.
Calcein-AM was from Molecular Probes, Inc. (Eugene,
OR). PEDF originating from afﬁnity-puriﬁed supernatants
of transfected baby hamster kidney cells was provided by
Millipore (Schwalbach, Germany).
Animals
All animals were treated according to the association for
research in vision and ophthalmology (ARVO) statement
on the use of animals in ophthalmic and vision research,
and all animal experiments were reviewed and approved by
municipal and University Hospital animal care committees
in Leipzig. TC is holding authorization #T97/11 for animal
experimentation, delivered by the state of Saxony. P7
BALB/c mice and Long-Evan rats were obtained from the
central animal facility of the medicine faculty in leipzig
(MEZ). For RGC preparation newborn mice were rapidly
decapitated, and for preparation of RPE and glial cells rats
were euthanized using overdoses of carbon dioxide. Mouse
and rats eyes were immediately collected and retina dis-
sected thereafter.
Immunoisolation and Culture of RGC from Postnatal
Mouse Retinae
Seven days old mice were killed according to institutional
guidelines. To isolate RGC, retinae were dissected and
incubated for 45 min at 37 C in Dulbecco’s phosphate
buffered saline (D-PBS; (Gibco/Invitrogen, Karlsruhe,
Germany) containing 160 U/ml papain, 200 U/ml DNAse.
The tissues were then sequentially triturated in D-PBS
containing 0.15% trypsin inhibitor (Roche Diagnostics,
Meylan, France), 650 U/ml DNAse and 1:75 rabbit anti-rat
macrophage antibody. Cells were spun down (8000g for
13 min), resuspended in 1% trypsin inhibitor in D-PBS,
spun down again and then resuspended in D-PBS con-
taining 0.02% bovine serum-albumin (fraction V; Sigma).
Cell suspension was ﬁltered through a nylon-mesh (Nitex
20 lm, Tetko/Sefar Filtration, Ru ¨schlikon, Switzerland)
and sequentially added to immunopanning plates. Brieﬂy,
immunopanning was performed using two subtraction
plates (150-mm diameter petri dishes; Falcon; BD Biosci-
ence, Heidelberg, Germany) coated with goat anti-rabbit-
IgG (Jackson Immunoresearch Laboratories/Beckman
Coulter, Marseille, France; 10 lg/ml) to remove microglial
cells after incubation of the supernatant with anti-macro-
phage antibody (WAK Chemie, Steinbach Germany).
Positive cell isolation was then achieved by incubating the
ﬁltrated supernatant for 45 min on a 100-mm diameter
petri dish sequentially pre-coated with goat anti-mouse-
IgG (Jackson Immunoresearch Laboratories) and anti-
Thy1.2 (mouse IgM, clone F7D5; Serotec, Du ¨sseldorf,
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123Germany). Non-adherent cells were thoroughly washed off,
and the bound cells were released by trypsination
(12,000 U/ml in Hank’s buffered salt solution [HBSS] for
10 min in 5% CO2 at 37 C) and resuspended in culture
medium. The average yield, in thousands, of RGC per
animal was 27.8 (±3.3), n = 11. RGC were plated at
600 cells mm
-2 on glass coverslips (10 mm in diameter)
centered on 12-well tissue culture plates (Greiner, Fric-
kenhausen, Germany), which were pre-coated with 5 lg/ml
poly-D-lysine (MW–40 kDa). Neurons were cultured for a
week at 37 C, 5% CO2, 95% humidity in Neurobasal
medium (Gibco/Invitrogen) supplemented with penicillin
(100 U/ml)/streptomycin (100 lg/ml) and pyruvate (1 mM),
glutamine (2 mM; Gibco/Invitrogen), N-acetyl-L-cysteine
(60 lg/ml), putrescine (16 lg/ml), selenite (40 ng/ml),
bovine serum albumin (100 lg/ml; fraction V, crystalline
grade), triiodothyronine (40 ng/ml), holotransferrin (100 lg/
ml), dibutyryl cyclic AMP (250 lM), insulin (5 lg/ml),
progesterone (62 ng/ml), B27 (1:50, Gibco/Invitrogen),
D-mannose (50 lM), brain-derived neurotrophic factor
(BDNF; 25 ng/ml; PeproTech, London, UK), ciliary neu-
rotrophic factor (CNTF; 10 ng/ml; PeproTech) and forskolin
(10 lM). Cell viability was checked by examining the cell
cultures under a phase contrast microscope (AxioVert25,
Carl Zeiss, Jena, Germany) and determining cell adherence
to the cover slip and the fraction of cells developing neurites.
We waited a week in order to let RGC develop a massive
neuritic arborisation. Since we were interested in the effect
of PEDF on neuronal survival rather than on neurite growth,
only preparations exhibiting an important development of
neurites were selected for further tests.
Isolation and Culture of Primary rat RPE and Retinal
Glial Cells
Primary RPE cells were prepared from 6- to 9-days old
rats as previously described [37]. The cells were isolated
after mechanical removal and disruption of the RPE with
subsequent enzymatic digestion using 0.05% trypsin/
0.02% EDTA. RPE cells were cultured in a medium
consisting of Ham’s-F10 supplemented with 10% fetal calf
serum, 100 U/ml penicillin, and 100 lg/ml streptomycin.
Primary retinal Mu ¨ller cells were prepared from 6- to
9-days old rats as described previously [38]. Brieﬂy, after
animal death, eyes were removed and isolated retinae were
dispersed for 30 min at 37 Ci nC a
2?- and Mg
2?-free
phosphate buffer supplemented with 1 mg/ml bacterial
protease nagarse (subtilisin A, MP Biomedicals; Eschwe-
ge, Germany). After washing in phosphate buffer con-
taining DNase I (200 U/ml), the dissociated cells were
plated on glass coverslips and cultured in minimal essen-
tial medium supplemented with 10% FCS. Most of the
cultured cells (*96%) expressed immunoreactivity for
vimentin and were positively stained for glial ﬁbrillary
acidic protein.
Homotyopic Culture, Co-culture and Hypoxia
Homotypic RGC Culture
After 1 week in vitro, the fully supplemented medium was
changed to a minimal medium without growth factors for
24 h. Cells were then maintained under either normoxic
(95% air, 5% CO2) or hypoxic conditions (0.2% O2,5 %
CO2, 94.8% N2) for an additional 24 h in the minimal
neurobasal medium, supplemented by 0, 1, 5 or 25 ng/ml
PEDF or 10 ng/ml CNTF. The CNTF treatment was used
as a control for optimal survival as its role in RGC neu-
roprotection has been largely demonstrated [35].
Co-culture
Primary rat Mu ¨ller cells were cultured up to 90% of con-
ﬂuence. Prior to setup of the co-cultures, coverslips were
brieﬂy washed in HBSS (Invitrogen). Two cover slips with
Mu ¨ller cells (8.6 9 10
4) and one with RGC (*5 9 10
4)
were co-cultured in a single 9.6 cm
2-well of a 6-well plate
(Greiner) for 24 h in a minimal neurobasal medium con-
taining all previously cited components with the exception
of BDNF and CNTF. This approach resulted in physical
separation of the two cell populations but allowed access to
media in each of the wells. Control experiments included
homotypic RGC cultures. As we were interested in the
neuroprotective role of glia-derived PEDF, co-cultures and
homotypic RGC cultures were maintained in minimal
neurobasal medium under either normoxic (95% air, 5%
CO2) or hypoxic conditions (0.2% O2,5 %C O 2, 94.8% N2)
for an additional 24 h. Culture medium was supplemented
by PEDF at different concentrations, CNTF (10 ng/ml) or
preservative-free bioactivity-neutralizing rabbit anti-PEDF
(PEDF1; 3 lg/ml; BioProducts Maryland, Middletown,
USA) as indicated in the result section. Normal rabbit IgG
(Dianova, Hamburg, Germany) was used as a control
reagent.
Survival Assays
RGC survival was assessed using a live-dead assay
(Invitrogen) based on intracellular hydrolysis of calcein
acetoxymethyl ester (calcein-AM) in living cells. Total
number of cells was assessed by counter-staining with
4’-6-diamidino-2-phenylindole (DAPI). After incubation in
normoxic or hypoxic conditions for 24 h, coverslips with
RGC were incubated with 2 lM calcein acetoxymethyl
ester for 30 min. The cells were washed using D-PBS,
ﬁxed in 4% paraformaldehyde solution for 15 min, washed
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1233 times in PBS before incubation in DAPI for 10 min
followed by 3 ﬁnal washes. Coverslips were mounted on
microscope slides using Fluoromount G (Science Services,
Mu ¨nchen, Germany). The slides were subsequently ana-
lyzed using a ﬂuorescence microscope (AxioVision, Zeiss,
Jena, Germany). Ten visual ﬁelds per coverslip were ran-
domly chosen and the total amount of RGC and number of
viable RGC per each ﬁeld was assessed to give a survival
percentage. We counted as living, cells labelled with both
DAPI and calcein-AM exhibiting neurite arborisation and
as dead, cells labelled only by DAPI and also cells
exhibiting a pyknotic nucleus labelled with both DAPI and
calcein, without neurite extension.
Real-Time RT-PCR
Both RPE and Mu ¨ller glial cells were passed at least once
to avoid any neuronal contamination and cultured to con-
ﬂuence before RNA isolation. Total RNA from rat RPE
and Mu ¨ller cells was then prepared, treated with DNase I
(Invitrogen), and subjected to reverse transcription using
standard procedures. Aliquots of cDNA (2 ll) were
ampliﬁed using a SYBR green assay (Bio-Rad, Munich,
Germany). The PCR products were routinely analyzed by
agarose gel electrophoresis and sequenced by intramural
facility. Real time PCR included 0.2 lM of primers spe-
ciﬁc for DNA segments of rat PEDF (50- CATGACATA
GACCGAGAACTG -30 and 50- AAGGACTGTAGCTTCA
TGTCC -30), or beta-actin (50- GAAACTACATTCA
ATTCCATC-30 and50-GGAGCAATGATCTTGATCTT-3).
The PCR mix was denatured at 95 C for 6 min, followed
by 45 cycles of melting at 95 C for 10 s, annealing at
58.5 C for 25 s, and elongation at 72 C for 25 s. All PCR
data were checked for homogeneity by dissociation curve
analysis. Fluorescence changes were monitored after each
cycle, Ct (threshold cycle) values for ampliﬁcation of
PEDF and b-actin mRNA were deﬁned, and the level of
PEDF mRNA in each sample was standardized to the
endogenous b-actin level. Comparable efﬁciencies for
PEDF and b-actin mRNA ampliﬁcation were determined
by analyzing serial cDNA dilutions. Relative PEDF mRNA
were expressed as 2
-DCt with DCt = CtPEDF–Ctb-actin.
Immunohistochemistry
Adult mouse eye were prepared for cryosection by
immersion in 4% formaldehyde solution in PBS for 1 h,
followed by increased sucrose gradients (10, 20 and 30% in
PBS). Eyeballs were embedded in TissueTek cryomedium
(Miles Eckhart, USA). Cryosections (10 lm) were col-
lected on Superfrost Plus (thermo ﬁscher scientiﬁc) glass
slides. Aspeciﬁc epitopes were blocked and cells were
permeabilized using a solution of 30% casblock
(Invitrogen) and 0.2% Triton 9100 in PBS for 30 min at
RT. Primary mouse anti- cellular retinaldehyde binding
protein (cralbp; NB100-74392 from Novus biological,
Littelton, USA) and goat anti-PEDF (AF1149; R&D Sys-
tems Wiesbaden Germany) antibodies were used overnight
at 4 C at 1/1,000 and 1/500 respectively in PBS, casblock
3, 0.02% triton 9100. Corresponding secondary antibodies
coupled to Alexa 488 for anti-mouse and Alexa 555 for
anti-goat were selected from Invitrogen and used at 1/500
for 1 h at RT. Finally, a DAPI (Invitrogen) nuclear staining
was achieved in the last washing steps. Slides were
mounted with Fluoromount-G (EMS, Hatﬁeld, USA),
observed using a Zeiss Axioplan 2 ﬂuorescent microscope
and picture taken with a Axiocam MRc5 digital camera
coupled to AxioVison 4.6 software (Carl Zeiss). Control
assays omitting primary antibodies conﬁrmed the speci-
ﬁcity of the staining (data not shown).
Data Analysis
Each experiment was at least repeated 3 times per condi-
tions. Bar diagrams display the means of RGC survival
rate (±SEM). Comparisons between the means across
all experimental conditions were made by analysis of
variance (ANOVA). P\0.05 was considered statistically
signiﬁcant.
Results
PEDF mRNA and Protein Expression in Glial Mu ¨ller
Cells and Effect of PEDF on RGC Survival
To evaluate the signiﬁcance of Mu ¨ller-cell related PEDF
production in the retina we ﬁrst compared their PEDF
mRNA level to that of those cells thought to be main pro-
ducers of PEDF in the eye, viz. RPE cells. Semi-quantita-
tive real-time PCR analysis revealed that in vitro, level of
PEDF mRNA in rat Mu ¨ller and RPE cells were comparable
(Fig. 1a). Relative PEDF mRNA levels (in thousands)
related to b-actin were found to be 27.3 ± 2.0 in rat Mu ¨ller
cells and 17.6 ± 2.7 in rat RPE cells (n = 4). As we were
testing in this study the effect of PEDF on mouse RGC we
therefore analyzed the localisation of PEDF in mouse ret-
ina. We used the cralbp antibody to speciﬁcally label Mu ¨ller
glial cell within the retina. In addition to typical radial
morphology of Mu ¨ller cell in the retinal compartment,
cralpb also label RPE and choroid (Fig. 1b). PEDF antibody
revealed a highly similar localization. PEDF was found in
cell structures running radially through the retinal layers
from the outer to the inner limiting membranes (Fig. 1c).
Merged image conﬁrmed that, within the retina, PEDF was
present in Mu ¨ller glial cell (Fig. 1d). Signal was found
Neurochem Res (2012) 37:1524–1533 1527
123especially strong at their large end feet (long arrow in
Fig. 1c, d) in close contact with the nearby RGC, visualized
using DAPI nuclear staining (Fig. 1d). PEDF staining was
also found in the RPE but no signal was detected in the
choroid as the limit of the double staining marked the
Bruch’s membrane (asterisk in Fig. 1d). Based on those
observations we then aimed to determine whether PEDF
was able to exert a direct neuroprotective activity on pure
RGC culture. We observed that hypoxia (0.2% O2) causes a
compromised survival of RGC when stained by calcein-
AM, which diffuses through cell membranes and is cleaved
in the living cell by non-speciﬁc esterases to generate a
ﬂuorescent product, calcein. (Fig. 2a) When counting the
number of calcein positive RGC versus the total number of
cells in the ﬁeld we found a ratio signiﬁcantly reduced
(
  P\0.01) in hypoxic condition versus normoxia
(Fig. 2b). Under normoxia, RGC survival in absence of
growth factor was 50.3 ± 0.1% and dropped to
33.0 ± 4.3%. However, addition of PEDF (range 0.02–
0.5 nM [1–25 ng/ml]) to RGC cultures resulted in a dose-
dependent increase of RGC survival, under normoxia
(53.6 ± 2.5%; 60.4 ± 2.3%; and 69.1 ± 4.5% with 1, 5
and 25 ng/ml of PEDF respectively) that reached signiﬁ-
cance for the two higher doses of PEDF (**P\0.01). This
neuroprotective effect was also found under hypoxia (0.2%
O2) as RGC survival increased along with PEDF concen-
tration (33.3 ± 3.9%; 38.8 ± 5.4%; 49.0 ± 6.0%); how-
ever, survival rate was found signiﬁcantly improved only
with 25 ng/ml PEDF (**P\0.01). CNTF was previously
reported as a strong survival factor for RGC [35] and was
used here to compare the efﬁciency of PEDF treatments.
We found a survival of 80.7 ± 5.7% under normoxia and
only 54.1 ± 1.9% under hypoxia that was signiﬁcantly
higher than control culture in normoxia and hypoxia
(**P\0.01). With the 25 ng/ml treatment we signiﬁcantly
increased the RGC survival in both normoxia and hypoxia.
The survival rate did not reach a plateau in normoxia,
however under hypoxia, 25 ng/ml PEDF had a nearly
similar neuroprotective effect as CNTF treatment.
Complex Secretions from Mu ¨ller Cells Enhance
the Viability of Retinal Ganglion Cells
Given the deposition of RPE-synthesized PEDF in the in-
terphotoreceptor matrix [39], we hypothesized that the
majority of PEDF produced by RPE cells is barely acces-
sible across the retina and thus would be an inappropriate
means to protect RGC from survival-compromising insults.
We therefore investigated the possibility that Mu ¨ller-cell
derived PEDF acts as a neuroprotectant for RGC. In an
approach in vitro, we performed co-cultures of Mu ¨ller cells
and RGC under normoxia and hypoxia (0.2% O2),
respectively, and determined RGC survival. Inspection of
RGC after 24 h (n = 6) revealed 65.9 ± 4.4% and
42.2 ± 3.5% viable cells under normoxia and hypoxia,
respectively, when the cells were co-cultured with primary
Fig. 1 PEDF expression in rodent retina a relative expression of
PEDF mRNA in rat Mu ¨ller glia cells related to b-actin compare to rat
RPE cells in vitro (in thousands). There was no statistical differences
(n = 4) and therefore expression levels are comparable in both cell
types in vitro suggesting that Mu ¨ller glia cell is a source of PEDF
within retina. b–d Immunohistological staining of mouse adult retina
with antibodies against cralbp (b), and PEDF (c) and the resulting
merged image d together with nucleus marker DAPI. Cralbp staining
reveales the typical Mu ¨ller glial cells morphology running radially
through the entire retina thickness from the outer limiting membrane
(OLM) to the inner limiting membrane (ILM) where the glia cells
extend large end feet (long arrow in b–d) embedding the retinal
ganglion cell (RGC) bodies. Retinal pigmented epithelium (RPE)
cells are heavily stained with both cralbp and PEDF antibody,
suggesting a high synthesis of this growth factor. Note the clear
exclusion zone of PEDF staining above the RPE layer delimiting the
Bruch’s membrane (BM, black asterisk in d). Within the neural
retina, PEDF staining co-localizes mainly with cralbp in Mu ¨ller glial
cells. The signal is particularly strong at their end feet (long arrow in
b, c, d) in close vicinity to RGC. In addition, in the outer plexiform
layer corresponding to the photoreceptor synapses area, PEDF is seen
in structures devoid of cralbp staining probably accounting for
perivascular structure and/or extracellular deposit (small arrow in c,
d). ONL: outer nuclear layer; INL: inner nuclear layer; IPL: inner
plexiform layer; scale bar in b:2 0lm
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123rat glial (Mu ¨ller) cells. In contrast, homotypic RGC cul-
tures demonstrated a cellular survival amounting to
47.3 ± 4.8% and 27.9 ± 3.5% of the total cell number
under normoxia and hypoxia, respectively. Thus the sur-
vival rate of RGC was signiﬁcantly (P\0.05) higher
when cultured together with Mu ¨ller cells than alone, each
under normoxia and hypoxia. Also, in hypoxia we have
consistently detected a signiﬁcantly (P\0.05) reduced
number of viable RGC even in co-culture with Mu ¨ller cells
(Fig. 3). However, if we analyse the increase of survival in
co-cultures versus homotypic ones we found a increase
of ? 42.1 ± 7.1% in normoxic condition and ? 55.8 ±
11.4% in hypoxic condition when Mu ¨ller glial cells are
present. These data indicate that hypoxia compromises the
viability of RGC and that Mu ¨ller cells release (a) neuro-
protective factor(s), which is (are) able to compensate
apoptotic loss of RGC.
PEDF Accounts for the Neuroprotective Mu ¨ller-Cell
Derived Activity
To determine whether Mu ¨ller-cell derived PEDF contrib-
utes to the observed neuroprotection, a neutralizing anti-
PEDF antibody was added to the cultures (Fig. 4). We
previously used this antibody to neutralize PEDF-mediated
functions in retinal endothelial cells [9] and employed it
here at 3 lg/ml to fully deplete the glia-conditioned med-
ium from PEDF. Under normoxic and hypoxic conditions,
the increasing survival rate induced by Mu ¨ller-cell derived
soluble mediators (71 ± 6% and 46 ± 2% respectively)
was signiﬁcantly impaired by the antibody treatment of
co-cultures with a resulting survival rate of 50 ± 6% and
34 ± 3% in normoxia and hypoxia respectively. In
homotypic RGC cultures, there was no effect of antibody
treatment on RGC survival, which amounted to a level
similar to that in the absence of PEDF, indicating the
absence of antibody toxicity toward RGC (data not shown).
Overall, these results suggest that PEDF represents an
essential soluble mediator contributing to the survival-
enhancing activity of Mu ¨ller cell-derived factors.
Discussion
RGC are subjected to neuronal death under various path-
ogenic conditions. Among those is glaucoma, a chronic
neurodegenerative disease in which RGCs ultimately die
from apoptosis in response to complex and multifaceted
Fig. 2 RGC survival under normoxia and hypoxia Survival of RGC
under normoxia and hypoxia (0.2% O2). RGC were cultured for 24 h
in a growth factor-deprived medium and survival was determined as
indicated in the ‘‘Materials and Methods’’ section. a Representative
sections of calcein-AM stained (green) RGC cultures maintained for
24 h under normoxia (left panel) or hypoxia (right panel) are shown.
Cell nuclei were counterstained with DAPI (blue, scale bar,5 0lm).
b PEDF enhances survival of RGC under normoxia and hypoxia.
RGC survival (ratio of living cell vs. total cells) was measured after
treatment with 0, 1, 5 and 25 ng/ml PEDF or 10 ng/ml CNTF (n = 3;
treated versus normoxic or hypoxic PEDF-free cultures, *P\0.05,
**P\0.01; control hypoxic versus normoxic PEDF-free control
culture, **
  P\0.01). RGC cultures treated with CNTF (bars in
grey) were taken as a reference for optimal survival
Fig. 3 RGC and Mu ¨ller glial cell co-cultures. Survival of RGC under
normoxia or hypoxia (0.2% O2) and in the absence (-) or presence
(?; bars in grey) of co-cultured primary Mu ¨ller glial cells. Signiﬁcant
differences to cultures without Mu ¨ller cells (*P\0.05, **P\0.01)
and to corresponding normoxic conditions (
••P\0.01,
•••P\0.001)
are indicated (n = 6)
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123insults including ischemia, which can be due to elevated
intraocular pressure, hypoxia, glutamate excitotoxicity, and
oxidative stress [40]. PEDF has been show to exhibit
neuroprotective properties on RGC in case of glutamate
excitotoxicity [17] and of elevated intraocular pressure [22,
30, 31], indicating its potential use in the development of
therapeutic strategies to ﬁght glaucoma, the second leading
cause of blindness after cataract worldwide.
Here we demonstrate for the ﬁrst time the direct neu-
roprotective role of PEDF on RGC. We compared mRNA
levels of this factor expressed by RPE and glia cells and
showed that PEDF is a glia-secreted factor that protects
RGC from a hypoxic insult. Altogether, our results suggest
that PEDF could constitute an essential survival factor for
RGC when released by Mu ¨ller glial cells in response to a
pathological state. Neuroprotective functions of PEDF
have largely been described in various neuronal types.
PEDF prevents glutamate-induced apoptotic cell death in
the CNS in general [15, 16, 41] and in the retina in par-
ticular [42]. In this study, we are underlining the contri-
bution of PEDF originating from Mu ¨ller glial cells in the
neuroprotection of RGC. Apart form the RPE, the canon-
ical source of PEDF in the eye, immunohistological anal-
ysis of mouse retina clearly showed that PEDF signal was
maximal in Mu ¨ller glia endfeet. We cannot fully rule out
the fact that some of the PEDF we detected in glia cell may
have come from a RPE secretion taken up by Mu ¨ller glial
cells rather than from a synthesis in situ, however this is
highly unlikely considering the similar expression level of
PEDF mRNA in those two cell types in vitro. Even if we
assessed PEDF transcript levels in cultured cells rather than
cells originating from in vivo material it is reasonable to
assume that both retinal glial (Mu ¨ller) and RPE cells pro-
duce a comparable amount of PEDF in situ. PEDF syn-
thesized by Mu ¨ller glial cells may be secreted in vivo at
glial cell endfeet, in the vicinity of the RGC bodies, and
may counterbalance a neurodegenerative insult targeting
this cell type. As recently shown [33], when injected in the
subconjunctiva, ﬂuorescent serpin is mainly found in
photoreceptor layer and do not reach the RGC layer after
24 h. This suggests that PEDF secreted at the RPE layer
could barely have a neuroprotective effect on RGC and our
present results using co-culture and PEDF neutralizing
antibody strongly support the hypothesis of a Mu ¨ller glial
contribution in this mechanism.
Interestingly co-culture with Mu ¨ller glial cell under
hypoxic condition did not fully protect RGC. The survival
was 42.2 ± 3.5% in hypoxic co-culture versus homotypic
RGC culture while co-culture improved the survival at
65.9 ± 4.4% in normoxic condition. The apparent reduced
efﬁciency of Mu ¨ller glial neuroprotection may be linked to
changes in the level of released survival factors and/or to the
noxiouseffectofadditionalfactorssecretedbyreactiveglial
cell; forming the Janus face of the reactive glia [43, 44].
However if one focus on the cell survival improvement, the
co-culture with Mu ¨ller glial cells increased RGC survival in
the same order of magnitude in normoxic and hypoxic con-
ditions. Efﬁciency on neuroprotection in the co-culture was
also found similar to the growth factor addition in the med-
ium using PEDF at 25 ng/ml. This optimal neuroprotection
underhypoxiaobtainedwithaPEDFconcentrationof25 ng/
ml is very similar to the optimal PEDF concentration to
achieve neuroprotection of RGC under glutamate insult,
with an EC50 value at 13.5 ng/ml [17]. Last but not least,
neutralizinganti-PEDFadded toco-cuturereducedthe RGC
survivaltoitsminimalvalues.Altogetherourresultssuggest
thatPEDFisthereforeoneofthereleasedfactorssecretedby
glia cell that could directly protect RGC in case of various
insults. In addition, we have previously shown that mRNA
expression of PEDF is modulated in Mu ¨ller glial cells by
hypoxic condition [8, 10]. However, at the protein level,
PEDFsecretionwasfoundsimilarundernormoxiccondition
and stronghypoxia[10]. Therefore,the precise regulationof
thisfactor byglialcellinvivofollowingahypoxicstresshas
still to be analyzed as several studies underlined by their
apparent discrepancy the complex regulation of PEDF
expression in this pathological condition [8, 10, 45–47].
As PEDF released from glial cell has been shown here to
be as efﬁcient as CNTF treatment, understanding its reg-
ulation and being able to stimulate its secretion by the
Mu ¨ller glial cell in vivo would consist in a promising
strategy to achieve neuroprotection of the RGC by their
close glial partner. Mu ¨ller glial cells are indeed the
Fig. 4 Effect of neutralizing anti-PEDF antibody Mu ¨ller cell-pro-
moted RGC survival in co-cultures is suppressed by a neutralizing
anti-PEDF antibody in both normoxic and hypoxic conditions (n = 4;
anti-PEDF vs. control cultures, *P\0.05; control hypoxic versus
normoxic control cultures,
•P\0.05). Co-cultures were maintained
in the presence of an anti-PEDF antibody (?) or normal goat
immunoglobulin in control cultures (-)
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123principal glial type of the retina and span the entire
thickness of this tissue, ensheathing all neurons. This glial
cell type can be called a ‘‘retinal swiss knife’’ that achieves
a multitude of functional interactions with neurons under
normal and pathological conditions [43]. In response to
virtually all type of insult (retinal detachment, glutamate
toxicity, hypoxia) Mu ¨ller glial cells undergo an early step of
reactive gliosis [44] characterized by changes in their
intermediate ﬁlament composition [48], activation of extra-
cellular signal-regulated kinase (ERKs) [49], and release of
neuroprotective factors [10, 50, 51]. During this early step,
gliosis is thought to be mainly neuroprotective and may
reﬂect an attempt to rescue retinal neurons from further
damage. By contrast, later gliotic events such as dediffer-
entiation,glialproliferation,andglialscarformation,largely
contribute to neuronal cell death. The balance between
beneﬁcial and detrimental events in reactive gliosis is
therefore a critical point in retinal neuroprotection, and
inﬂuencing this balance ‘‘in situ’’ could lead to therapeutic
strategies in ﬁghting various retinopathies. Interestingly,
high levels of survival factor(s), normally secreted by reac-
tive Mu ¨ller glial cells, are able to keep the gliosis under
controlbysuppressingthedetrimentalproliferativeresponse
of Mu ¨ller glial cells [52]. PEDF itself has been shown to
preserve the expression of glutamine synthetase level, to
downregulate GFAP expression in reactive gliosis, and to
preventthe degenerative glial response in retina by reducing
the inﬂammatory state of Mu ¨ller glial cells [31, 53, 54].
IncreasingthePEDFcontentspeciﬁcallyinMu ¨llerglialcells
through transfection [55] or transplantation [56] may result
in original strategies to take advantage from its neuropro-
tective properties towards RGC, along with the global ben-
eﬁcial response of glia, while avoiding the detrimental
consequence of a massive gliosis in response to neurode-
generative stimuli.
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